news
FDA approves Admelog, the first follow-on insulin product to treat diabetes
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
List view / Grid view
Type 2 Diabetes
news
A risk factor for drug-induced skin disease identified
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
news
FDA approves Bydureon BCise for patients with type-2 diabetes
The FDA has approved Bydureon BCise for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines...
news
Oral semaglutide shows promise for type 2 diabetes
Researchers have identified that the drug semaglutide resulted in better glycemic control than placebo for patients with type 2 diabetes...
article
2017 pipelines: Analysing future trends in the $12billion diabetes market
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
news
LixiLan-O and LixiLan-L meet primary endpoints
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
news
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
news
Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
news
Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet
15 August 2013 | By OgilvyHealthPR London
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…
news
First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes
31 July 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…
news
Roche halts investigation of aleglitazar following regular safety review of phase III trial
10 July 2013 | By Roche
"The safety of patients is our first priority..."
news
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
25 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of…
news
Abbott announces CE Mark for test to aid doctors with diagnosing and monitoring diabetes
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.
news
Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
news
Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes
8 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…
